Search

CAR T-cell therapy approved in Scotland

Standard post

… large B-cell lymphoma (DLBCL) that has not responded ( refractory ) or has come back ( relapsed ) after two or more … benefits of tisagenlecleucel for people with relapsed or refractory DLBCL outweigh its costs. The treatment has since …

New SMC guidance for DLBCL

Standard post

… B-cell lymphoma (HGBL) , which has not responded to (refractory) or come back (relapsed) after chemoimmunotherapy. … in Scotland with DLBCL and HGBL who have relapsed or refractory disease. It is only to be used in those patients …

CXD101 drug active in several types of lymphoma

Standard post

… but their lymphoma had relapsed (come back) or was refractory (didn’t respond) to their previous treatment. The … dose is being tested in more people with relapsed and refractory lymphoma and advanced cancer. Find out more about …

Clinical trials update from the ASH conference

Standard post

… be able to tolerate traditional chemotherapy. Relapsed and refractory Hodgkin lymphoma Two trials reported encouraging … for brentuximab vedotin–based approaches to relapsed or refractory Hodgkin lymphoma. In a phase 1/2 trial , people with relapsed or refractory Hodgkin lymphoma were treated with a combination …

SMC recommends Pola BR

Standard post

… BR) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not …